Europe — EMA
Oxbryta (Voxelotor)
Voxelotor, the active ingredient in Oxbryta, is a disease-modifying therapy presented as a tablet for oral use. It is indicated for the treatment of sickle cell disease in adults and pediatric patients.
Request sourcing
What is Voxelotor?
Voxelotor, the active ingredient in Oxbryta, is a disease-modifying therapy presented as a tablet for oral use. It is indicated for the treatment of sickle cell disease in adults and pediatric patients. GNH USA supplies Oxbryta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Oxbryta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.
What is Voxelotor used for?
Oxbryta is used to manage sickle cell disease, a genetic disorder that affects hemoglobin function.
- Sickle cell disease: Improves hemoglobin oxygen affinity and reduces hemolysis. - Chronic anemia associated with sickle cell disease: Increases hemoglobin levels. - Vaso‑occlusive crises: Decreases the frequency of episodes of pain and hospital visits. - Related
What are the side effects of Voxelotor?
The
